Eli Lilly widens obesity reach with $1.4B KeyBioscience deal
by
Contributor since / Followers
Contributor since / Followers
3 months ago
jetcityimage/iStock Editorial via Getty Images
In 2017, LLY partnered with KeyBioscience to develop DACRA-based therapies for type 2 diabetes and other metabolic disorders.
More on Eli Lilly
- Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
- Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
- Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
- Lilly threatens legal action against copycat Zepbound providers: report
- Weight-loss drugs: How much should investors worry about side effects?